Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5277396 | 0.85 | CA2 (0.65) | HTR6CA2CYP4F2CYP4A11TBXA2R | |
| SCHEMBL5429891 | 0.85 | CYP4F2 (0.51) | HTR6CA2CYP4F2CYP4A11MGLL | |
| SCHEMBL11266570 | 0.83 | LPL (0.57) | HTR6CA2LPLLIPG | |
| SCHEMBL11828390 | 0.83 | LPL (0.57) | HTR6CA2LPLLIPG | |
| SCHEMBL11426304 | 0.83 | LPL (0.57) | HTR6CA2LPLLIPG | |
| SCHEMBL2176833 | 0.81 | CYP4F2 (0.56) | CA2CYP4F2CYP4A11MGLLTBXA2R | |
| SCHEMBL6444977 | 0.81 | LPL (0.56) | HTR6CA2LPLLIPG | |
| SCHEMBL5662465 | 0.79 | TBXA2R (0.49) | HTR6CA2CYP4F2CYP4A11MGLL | |
| SCHEMBL5436203 | 0.79 | CA2 (0.64) | HTR6CA2CYP4F2CYP4A11TBXA2R | |
| SCHEMBL238401 | 0.79 | CYP4F2 (0.58) | CA2CYP4F2CYP4A11MGLLTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133274-A | TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS | CELL THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5780476-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS | CELL THERAPEUTICS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0669825-A4 | HYDROXYL-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0669825-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |